Autor: "Morgan, Gareth" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer.
Autorzy:: Ghamlouch H; Myeloma Research Program, NYU Langone Medical Center, Perlmutter Cancer Center, 522 1st Avenue, Manhattan, New York City, NY, 10016, USA. .
Boyle EM; Myeloma Research Program, NYU Langone Medical Center, Perlmutter Cancer Center, 522 1st Avenue, Manhattan, New York City, NY, 10016, USA.
Blaney P; Myeloma Research Program, NYU Langone Medical Center, Perlmutter Cancer Center, 522 1st Avenue, Manhattan, New York City, NY, 10016, USA.; Applied Bioinformatics Laboratories (ABL), NYU Langone Medical Center, New York, NY, USA.
Wang Y; Myeloma Research Program, NYU Langone Medical Center, Perlmutter Cancer Center, 522 1st Avenue, Manhattan, New York City, NY, 10016, USA.
Choi J; Myeloma Research Program, NYU Langone Medical Center, Perlmutter Cancer Center, 522 1st Avenue, Manhattan, New York City, NY, 10016, USA.
Williams L; Myeloma Research Program, NYU Langone Medical Center, Perlmutter Cancer Center, 522 1st Avenue, Manhattan, New York City, NY, 10016, USA.
Bauer M; Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Auclair D; The Multiple Myeloma Research Foundation (MMRF), Norwalk, CT, USA.
Bruno B; Myeloma Research Program, NYU Langone Medical Center, Perlmutter Cancer Center, 522 1st Avenue, Manhattan, New York City, NY, 10016, USA.
Walker BA; Division of Hematology Oncology, Indiana University, Indianapolis, IN, USA.
Davies FE; Myeloma Research Program, NYU Langone Medical Center, Perlmutter Cancer Center, 522 1st Avenue, Manhattan, New York City, NY, 10016, USA.
Morgan GJ; Myeloma Research Program, NYU Langone Medical Center, Perlmutter Cancer Center, 522 1st Avenue, Manhattan, New York City, NY, 10016, USA. gareth.morgan@nyulangone.org.; Pokaż więcej
Źródło:: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2021 Dec 02; Vol. 40 (1), pp. 380. Date of Electronic Publication: 2021 Dec 02.
Typ publikacji:: Journal Article; Review
MeSH Terms:: DNA-Binding Proteins/*metabolism
Multiple Myeloma/*genetics
Transcription Factors/*metabolism
Humans ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Survival Analysis

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma.
Autorzy:: Wong KY; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road, Pokfulam, Hong Kong.
Morgan GJ; NYU Langone Health, New York, NY, 10016, USA.
Boyle EM; NYU Langone Health, New York, NY, 10016, USA.
Cheng ASL; School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
Yip KY; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
Chim CS; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road, Pokfulam, Hong Kong. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2021 Mar 26; Vol. 11 (1), pp. 7009. Date of Electronic Publication: 2021 Mar 26.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Cytoskeletal Proteins/*genetics
Cytoskeletal Proteins/*metabolism
DNA Methylation/*genetics
Gene Expression Regulation, Neoplastic/*genetics
Multiple Myeloma/*genetics
Cell Line, Tumor ; Cell Proliferation/genetics ; CpG Islands/genetics ; Enhancer Elements, Genetic/genetics ; Humans ; Multiple Myeloma/pathology ; Promoter Regions, Genetic/genetics ; Proof of Concept Study ; RNA Interference ; RNA, Small Interfering/genetics ; Syndecan-1/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.
Autorzy:: Deshpande S; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Tytarenko RG; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Wang Y; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Boyle EM; Perlmutter Cancer Center, Myeloma Research Program, NYU Langone Health, New York, NY, USA.
Ashby C; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Schinke CD; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Thanendrarajan S; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Zangari M; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Zhan F; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Davies FE; Perlmutter Cancer Center, Myeloma Research Program, NYU Langone Health, New York, NY, USA.
Morgan GJ; Perlmutter Cancer Center, Myeloma Research Program, NYU Langone Health, New York, NY, USA.
van Rhee F; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Walker BA; Division of Hematology Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN, USA.; Pokaż więcej
Źródło:: European journal of haematology [Eur J Haematol] 2021 Feb; Vol. 106 (2), pp. 230-240. Date of Electronic Publication: 2020 Nov 10.
Typ publikacji:: Journal Article
MeSH Terms:: Biomarkers, Tumor*
Circulating Tumor DNA*
Multiple Myeloma/*genetics
Alleles ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bone Marrow ; Computational Biology/methods ; Disease Progression ; Genetic Variation ; High-Throughput Nucleotide Sequencing ; Humans ; Liquid Biopsy ; Multiple Myeloma/blood ; Multiple Myeloma/diagnosis ; Multiple Myeloma/therapy ; Prognosis ; Smoldering Multiple Myeloma/blood ; Smoldering Multiple Myeloma/diagnosis ; Smoldering Multiple Myeloma/genetics ; Smoldering Multiple Myeloma/therapy ; Treatment Outcome ; Tumor Burden ; ras Proteins/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Autorzy:: Jackson GH; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.
Pawlyn C; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.
Cairns DA; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
de Tute RM; Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, United Kingdom.
Hockaday A; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
Collett C; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
Jones JR; Kings College Hospital NHS Foundation Trust, London, United Kingdom.
Kishore B; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Garg M; Leicester Royal Infirmary, Leicester, United Kingdom.
Williams CD; Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom.
Karunanithi K; University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom.
Lindsay J; East Kent Hospitals University NHS Foundation Trust, Canterbury, United Kingdom.
Rocci A; Manchester University NHS Foundation Trust, Manchester, United Kingdom.; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Snowden JA; Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
Jenner MW; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Cook G; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.; Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom.
Russell NH; Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom.
Drayson MT; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
Gregory WM; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
Kaiser MF; The Institute of Cancer Research, London, United Kingdom.; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.
Owen RG; Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, United Kingdom.
Davies FE; Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States of America.
Morgan GJ; Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States of America.; Pokaż więcej
Corporate Authors:: UK NCRI Haemato-oncology Clinical Studies Group
Źródło:: PLoS medicine [PLoS Med] 2021 Jan 11; Vol. 18 (1), pp. e1003454. Date of Electronic Publication: 2021 Jan 11 (Print Publication: 2021).
Typ publikacji:: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Multiple Myeloma/*drug therapy
Adult ; Aged ; Cyclophosphamide/therapeutic use ; Dexamethasone/therapeutic use ; Female ; Humans ; Lenalidomide/therapeutic use ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Oligopeptides/therapeutic use ; Survival Analysis ; United Kingdom

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
Autorzy:: Danziger SA; Bristol Myers Squibb, Seattle, Washington, United States of America.
McConnell M; Bristol Myers Squibb, Seattle, Washington, United States of America.
Gockley J; Sage Bionetworks, Seattle, Washington, United States of America.
Young MH; Sage Bionetworks, Seattle, Washington, United States of America.
Rosenthal A; Cancer Research and Biostatistics, Seattle, Washington, United States of America.
Schmitz F; Sage Bionetworks, Seattle, Washington, United States of America.
Reiss DJ; Bristol Myers Squibb, Seattle, Washington, United States of America.
Farmer P; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Alapat DV; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Singh A; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Ashby C; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Bauer M; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Ren Y; Bristol Myers Squibb, Seattle, Washington, United States of America.
Smith K; Bristol Myers Squibb, Seattle, Washington, United States of America.
Couto SS; Genmab, Princeton, New Jersey, United States.
van Rhee F; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Davies F; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Zangari M; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Petty N; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Orlowski RZ; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Dhodapkar MV; Winship Cancer Institute, Emory University, Atlanta, Georgia, United States of America.
Copeland WB; Bristol Myers Squibb, Seattle, Washington, United States of America.
Fox B; Bristol Myers Squibb, Seattle, Washington, United States of America.
Hoering A; Cancer Research and Biostatistics, Seattle, Washington, United States of America.
Fitch A; Bristol Myers Squibb, Seattle, Washington, United States of America.
Newhall K; Sage Bionetworks, Seattle, Washington, United States of America.
Barlogie B; Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Trotter MWB; BMS Center for Innovation and Translational Research Europe (CITRE), Seville, Spain.
Hershberg RM; Sage Bionetworks, Seattle, Washington, United States of America.
Walker BA; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.
Dervan AP; Sage Bionetworks, Seattle, Washington, United States of America.
Ratushny AV; Bristol Myers Squibb, Seattle, Washington, United States of America.
Morgan GJ; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.; Pokaż więcej
Źródło:: PLoS medicine [PLoS Med] 2020 Nov 04; Vol. 17 (11), pp. e1003323. Date of Electronic Publication: 2020 Nov 04 (Print Publication: 2020).
Typ publikacji:: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Tumor Microenvironment*
Bone Marrow/*pathology
Multiple Myeloma/*diagnosis
Multiple Myeloma/*pathology
Adult ; Cohort Studies ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Prognosis ; Tumor Burden

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma.
Autorzy:: Choudhury SR; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Ashby C; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Tytarenko R; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Bauer M; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Wang Y; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Deshpande S; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Den J; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Schinke C; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Zangari M; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Thanendrarajan S; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Davies FE; Department of Medicine, NYU Langone Health, New York, NY, 10016, USA.
van Rhee F; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Morgan GJ; Department of Medicine, NYU Langone Health, New York, NY, 10016, USA.
Walker BA; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA. .; Division of Hematology Oncology, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN, 46202, USA. .; Pokaż więcej
Źródło:: Journal of hematology & oncology [J Hematol Oncol] 2020 Aug 06; Vol. 13 (1), pp. 108. Date of Electronic Publication: 2020 Aug 06.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Epigenesis, Genetic*
Epigenome*
Gene Expression Regulation, Neoplastic*
Gene Regulatory Networks/*genetics
Multiple Myeloma/*genetics
Aneuploidy ; Chromosomes, Human, Pair 11/genetics ; Chromosomes, Human, Pair 11/ultrastructure ; Chromosomes, Human, Pair 14/genetics ; Chromosomes, Human, Pair 14/ultrastructure ; Chromosomes, Human, Pair 4/genetics ; Chromosomes, Human, Pair 4/ultrastructure ; Cyclin D1/biosynthesis ; Cyclin D1/genetics ; Cyclin D2/biosynthesis ; Cyclin D2/genetics ; DNA Methylation ; DNA, Neoplasm/genetics ; DNA, Neoplasm/metabolism ; Gene Expression Profiling ; Gene Ontology ; Histone Code ; Histones/metabolism ; Humans ; Multiple Myeloma/classification ; Neoplasm Proteins/biosynthesis ; Neoplasm Proteins/genetics ; Plasma Cells/metabolism ; Promoter Regions, Genetic ; Proto-Oncogene Proteins c-maf/genetics ; Translocation, Genetic

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes.
Autorzy:: Mohan M; Myeloma Institute, Little Rock, Arkansas.
Susanibar-Adaniya S; Myeloma Institute, Little Rock, Arkansas.
Buros A; Myeloma Institute, Little Rock, Arkansas.
Crescencio JCR; Division of Infectious Diseases, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Burgess MJ; Hospital Pharmacy, UAMS Medical Center, Little Rock, Arkansas.
Lusardi K; Hospital Pharmacy, UAMS Medical Center, Little Rock, Arkansas.
Davies F; Myeloma Institute, Little Rock, Arkansas.
Morgan G; Myeloma Institute, Little Rock, Arkansas.
Vanrhee F; Myeloma Institute, Little Rock, Arkansas.
Zangari M; Myeloma Institute, Little Rock, Arkansas.
Schinke C; Myeloma Institute, Little Rock, Arkansas.
Thanendrarajan S; Myeloma Institute, Little Rock, Arkansas.
Kothari A; Division of Infectious Diseases, University of Arkansas for Medical Sciences, Little Rock, Arkansas.; Pokaż więcej
Źródło:: Transplant infectious disease : an official journal of the Transplantation Society [Transpl Infect Dis] 2019 Apr; Vol. 21 (2), pp. e13052. Date of Electronic Publication: 2019 Feb 15.
Typ publikacji:: Journal Article
MeSH Terms:: Bacteremia/*etiology
Multiple Myeloma/*therapy
Stem Cell Transplantation/*adverse effects
Adult ; Aged ; Aged, 80 and over ; Bacteremia/epidemiology ; Disease-Free Survival ; Female ; Gram-Positive Bacterial Infections/epidemiology ; Gram-Positive Bacterial Infections/mortality ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multiple Myeloma/complications ; Pseudomonas Infections/epidemiology ; Pseudomonas Infections/mortality ; Retrospective Studies ; Risk Factors ; Staphylococcal Infections/epidemiology ; Staphylococcal Infections/mortality ; Survival Analysis ; Transplantation, Autologous/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma.
Autorzy:: Chattopadhyay S; Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.; Faculty of Medicine, University of Heidelberg, Heidelberg, 69117, Germany.
Thomsen H; Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.
Yadav P; Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.
da Silva Filho MI; Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.
Weinhold N; University Clinic Heidelberg, Internal Medicine V, Heidelberg, 69117, Germany.; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 72205, AR, USA.
Nöthen MM; Institute of Human Genetics, University of Bonn, Bonn, 53127, Germany.; Department of Genomics, Life & Brain Research Center, University of Bonn, Bonn, 53127, Germany.
Hoffman P; Institute of Human Genetics, University of Bonn, Bonn, 53127, Germany.; Department of Genomics, Life & Brain Research Center, University of Bonn, Bonn, 53127, Germany.; Department of Biomedicine, University of Basel, Basel, 4003, Switzerland.
Bertsch U; University Clinic Heidelberg, Internal Medicine V, Heidelberg, 69117, Germany.
Huhn S; University Clinic Heidelberg, Internal Medicine V, Heidelberg, 69117, Germany.
Morgan GJ; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, 72205, AR, USA.
Goldschmidt H; University Clinic Heidelberg, Internal Medicine V, Heidelberg, 69117, Germany.; National Centre of Tumor Diseases, Heidelberg, 69120, Germany.
Houlston R; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.; Division of Molecular Pathology, The Institute of Cancer Research, London, SW7 3RP, UK.
Hemminki K; Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany.; Center for Primary Health Care Research, Lund University, 205 02, Malmö, Sweden.
Försti A; Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany. .; Center for Primary Health Care Research, Lund University, 205 02, Malmö, Sweden. .; Pokaż więcej
Źródło:: Communications biology [Commun Biol] 2019 Mar 04; Vol. 2, pp. 89. Date of Electronic Publication: 2019 Mar 04 (Print Publication: 2019).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Disease Susceptibility*
Genome-Wide Association Study*
Signal Transduction*
Multiple Myeloma/*etiology
Multiple Myeloma/*metabolism
Chromosome Mapping ; Gene Regulatory Networks ; Genetic Loci ; Genetic Predisposition to Disease ; Humans ; Multiple Myeloma/pathology ; Polymorphism, Single Nucleotide

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses.
Autorzy:: Yao Q; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road, Pokfulam, Hong Kong.
Morgan GJ; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Chim CS; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road, Pokfulam, Hong Kong. .; Pokaż więcej
Źródło:: Clinical epigenetics [Clin Epigenetics] 2018 Dec 20; Vol. 10 (1), pp. 158. Date of Electronic Publication: 2018 Dec 20.
Typ publikacji:: Case Reports; Letter; Research Support, Non-U.S. Gov't
MeSH Terms:: DNA Methylation*
Genetic Heterogeneity*
Multiple Myeloma/*genetics
Aged ; Clone Cells/chemistry ; Disease Progression ; Epigenesis, Genetic ; Female ; Humans ; Male ; Middle Aged ; Promoter Regions, Genetic ; Recurrence

Raport

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.
Autorzy:: Qiang YW; Myeloma Institute, University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, 4301 West Markham St., Slot 776, Rm 914, Little Rock, AR, 72205, USA. .
Ye S; Myeloma Institute, University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, 4301 West Markham St., Slot 776, Rm 914, Little Rock, AR, 72205, USA.
Huang Y; Myeloma Institute, University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, 4301 West Markham St., Slot 776, Rm 914, Little Rock, AR, 72205, USA.
Chen Y; Myeloma Institute, University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, 4301 West Markham St., Slot 776, Rm 914, Little Rock, AR, 72205, USA.
Van Rhee F; Myeloma Institute, University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, 4301 West Markham St., Slot 776, Rm 914, Little Rock, AR, 72205, USA.
Epstein J; Myeloma Institute, University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, 4301 West Markham St., Slot 776, Rm 914, Little Rock, AR, 72205, USA.
Walker BA; Myeloma Institute, University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, 4301 West Markham St., Slot 776, Rm 914, Little Rock, AR, 72205, USA.
Morgan GJ; Myeloma Institute, University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, 4301 West Markham St., Slot 776, Rm 914, Little Rock, AR, 72205, USA.
Davies FE; Myeloma Institute, University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, 4301 West Markham St., Slot 776, Rm 914, Little Rock, AR, 72205, USA.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2018 Jul 06; Vol. 18 (1), pp. 724. Date of Electronic Publication: 2018 Jul 06.
Typ publikacji:: Journal Article
MeSH Terms:: MafB Transcription Factor/*physiology
Multiple Myeloma/*drug therapy
Proteasome Inhibitors/*therapeutic use
Apoptosis/drug effects ; Caspases/metabolism ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Glycogen Synthase Kinase 3/antagonists & inhibitors ; Humans ; MafB Transcription Factor/analysis ; MafB Transcription Factor/genetics ; Multiple Myeloma/pathology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.
Autorzy:: Sriskandarajah P; a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.; b The Institute of Cancer Research , London , UK.
Pawlyn C; a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.; b The Institute of Cancer Research , London , UK.
Mohammed K; a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.
Dearden CE; a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.
Davies FE; a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.; c Myeloma Institute, University of Arkansas for Medical Sciences , Little Rock , AR , USA.
Morgan GJ; a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.; c Myeloma Institute, University of Arkansas for Medical Sciences , Little Rock , AR , USA.
Boyd KD; a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.
Kaiser MF; a Department of Haemato-Oncology , Royal Marsden Hospital , Sutton , UK.; b The Institute of Cancer Research , London , UK.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2017 Feb; Vol. 58 (2), pp. 494-497. Date of Electronic Publication: 2016 Jul 20.
Typ publikacji:: Letter
MeSH Terms:: Angiogenesis Inhibitors/*therapeutic use
Antineoplastic Agents/*therapeutic use
Multiple Myeloma/*drug therapy
Thalidomide/*analogs & derivatives
Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Combined Modality Therapy ; Drug Resistance, Neoplasm ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Multiple Myeloma/diagnosis ; Multiple Myeloma/mortality ; Neoplasm Grading ; Neoplasm Staging ; Recurrence ; Retreatment ; Thalidomide/administration & dosage ; Thalidomide/adverse effects ; Thalidomide/therapeutic use ; Treatment Outcome

Opinia redakcyjna

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci.
Autorzy:: Law PJ; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Sud A; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Mitchell JS; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Henrion M; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Orlando G; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Lenive O; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Broderick P; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Speedy HE; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Johnson DC; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
Kaiser M; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
Weinhold N; Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA.
Cooke R; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Sunter NJ; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
Jackson GH; Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Summerfield G; Department of Haematology, Queen Elizabeth Hospital, Gateshead, Newcastle upon Tyne, UK.
Harris RJ; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Pettitt AR; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Allsup DJ; Queens Centre for Haematology and Oncology, Castle Hill Hospital, Hull and East Yorkshire NHS Trust, UK.
Carmichael J; Queens Centre for Haematology and Oncology, Castle Hill Hospital, Hull and East Yorkshire NHS Trust, UK.
Bailey JR; Queens Centre for Haematology and Oncology, Castle Hill Hospital, Hull and East Yorkshire NHS Trust, UK.
Pratt G; Department of Haematology, Birmingham Heartlands Hospital, Birmingham, UK.
Rahman T; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
Pepper C; Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK.
Fegan C; Cardiff and Vale National Health Service Trust, Heath Park, Cardiff, UK.
von Strandmann EP; Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Engert A; Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Försti A; Division of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, Germany.; Centre for Primary Health Care Research, Lund University, Malmö, Sweden.
Chen B; Division of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, Germany.
Filho MI; Division of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, Germany.
Thomsen H; Division of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, Germany.
Hoffmann P; Institute of Human Genetics, University of Bonn, Germany.; Division of Medical Genetics, Department of Biomedicine, University of Basel, Switzerland.
Noethen MM; Institute of Human Genetics, University of Bonn, Germany.; Department of Genomics, Life &Brain Center, University of Bonn, Germany.
Eisele L; University of Duisburg-Essen, Essen, Germany.
Jöckel KH; University of Duisburg-Essen, Essen, Germany.
Allan JM; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
Swerdlow AJ; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.; Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.
Goldschmidt H; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.; National Center of Tumor Diseases, Heidelberg, Germany.
Catovsky D; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
Morgan GJ; Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA.
Hemminki K; Division of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, Germany.; Centre for Primary Health Care Research, Lund University, Malmö, Sweden.
Houlston RS; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2017 Jan 23; Vol. 7, pp. 41071. Date of Electronic Publication: 2017 Jan 23.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Genome-Wide Association Study*
Genetic Pleiotropy/*genetics
Hodgkin Disease/*genetics
Leukemia, Lymphocytic, Chronic, B-Cell/*genetics
Multiple Myeloma/*genetics
Adaptor Proteins, Signal Transducing/genetics ; Adult ; Aged ; Female ; Genetic Predisposition to Disease ; HLA-DQ beta-Chains/genetics ; HLA-DRB1 Chains/genetics ; Hodgkin Disease/pathology ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Male ; Middle Aged ; Multiple Myeloma/pathology ; Oncogene Proteins/genetics ; Polymorphism, Single Nucleotide/genetics ; Risk Factors

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Risk of multiple myeloma in a case-spouse study.
Autorzy:: Andreotti G; a Division of Cancer Epidemiology and Genetics , National Cancer Institute, NIH, DHHS , Rockville , MD , USA ;
Katz M; b International Myeloma Foundation , Hollywood , CA , USA ;
Hoering A; c Cancer Research and Biostatistics , Seattle , WA , USA ;
Van Ness B; d Cancer Center, University of Minnesota , Minneapolis , MN , USA ;
Crowley J; c Cancer Research and Biostatistics , Seattle , WA , USA ;
Morgan G; e Haemato-Oncology, Institute of Cancer Research , Sutton , UK ;
Hoover RN; a Division of Cancer Epidemiology and Genetics , National Cancer Institute, NIH, DHHS , Rockville , MD , USA ;
Baris D; a Division of Cancer Epidemiology and Genetics , National Cancer Institute, NIH, DHHS , Rockville , MD , USA ;
Durie B; b International Myeloma Foundation , Hollywood , CA , USA ;; f Cedar Sinai Medical Center , Los Angeles , CA , USA.; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2016; Vol. 57 (6), pp. 1450-9. Date of Electronic Publication: 2015 Nov 16.
Typ publikacji:: Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Spouses*
Multiple Myeloma/*epidemiology
Multiple Myeloma/*etiology
Adult ; Aged ; Aged, 80 and over ; Case-Control Studies ; Comorbidity ; Drug-Related Side Effects and Adverse Reactions ; Female ; Humans ; Male ; Middle Aged ; Occupational Exposure/adverse effects ; Occupations ; Odds Ratio ; Risk ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells.
Autorzy:: Meißner T; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. .; Department of Molecular and Experimental Medicine, Avera Cancer Institute, 11099 North Torrey Pines Road, La Jolla, CA, 92037, USA. .
Seckinger A; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. .
Hemminki K; Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. .; Center for Primary Health Care Ressearch, Lund University, Malmo, Sweden. .
Bertsch U; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. .
Foersti A; Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. .; Center for Primary Health Care Ressearch, Lund University, Malmo, Sweden. .
Haenel M; Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany. .
Duering J; Department of Hematology, University Hospital Essen, Essen, Germany. .
Salwender H; Department of Hematology and Oncology, Asklepios Hospital Hamburg Altona, Hamburg, Germany. .
Goldschmidt H; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. .; National Center for Tumor Diseases, Heidelberg, Germany. .
Morgan GJ; Myeloma Institute, Little Rock, AR, USA. .
Hose D; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.; National Center for Tumor Diseases, Heidelberg, Germany.
Weinhold N; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.; Myeloma Institute, Little Rock, AR, USA.; Pokaż więcej
Źródło:: BMC medical genomics [BMC Med Genomics] 2015 Dec 30; Vol. 8, pp. 85. Date of Electronic Publication: 2015 Dec 30.
Typ publikacji:: Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Databases, Genetic*
Gene Expression Profiling*
Gene Expression Regulation, Neoplastic*
Multiple Myeloma*/genetics
Multiple Myeloma*/metabolism
Specimen Handling*
Female ; Humans ; Male ; Time Factors

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma.
Autorzy:: Mitchell JS; Molecular and Population Genetics, Division of Genetics and Epidemiology, The Institute of Cancer Research, Surrey, UK.
Johnson DC; Department of Haemato-Oncology, Division of Pathology, The Institute of Cancer Research, Surrey, UK.
Litchfield K; Molecular and Population Genetics, Division of Genetics and Epidemiology, The Institute of Cancer Research, Surrey, UK.
Broderick P; Molecular and Population Genetics, Division of Genetics and Epidemiology, The Institute of Cancer Research, Surrey, UK.
Weinhold N; Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Davies FE; Department of Haemato-Oncology, Division of Pathology, The Institute of Cancer Research, Surrey, UK.
Gregory WA; Leeds Institute of Molecular Medicine, Section of Clinical Trials Research, University of Leeds, Leeds, UK.
Jackson GH; Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Kaiser M; Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, UK.
Morgan GJ; Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Houlston RS; Molecular and Population Genetics, Division of Genetics and Epidemiology, The Institute of Cancer Research, Surrey, UK.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2015 Jul 24; Vol. 5, pp. 12473. Date of Electronic Publication: 2015 Jul 24.
Typ publikacji:: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Genetic Predisposition to Disease*
Genome, Human*
Polymorphism, Single Nucleotide*
Quantitative Trait, Heritable*
Multiple Myeloma/*genetics
Case-Control Studies ; Genetic Variation ; Genome-Wide Association Study ; Humans ; Models, Genetic ; Multiple Myeloma/pathology ; Phenotype

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue.
Autorzy:: Wu P; Section of Haemato-Oncology.
Walker BA
Broyl A
Kaiser M
Johnson DC
Kuiper R
van Duin M
Gregory WM
Davies FE
Brewer D
Hose D
Sonneveld P
Morgan GJ; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2015 Mar; Vol. 56 (3), pp. 594-601. Date of Electronic Publication: 2014 Aug 19.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Gene Expression Profiling*
Stem Cell Transplantation*
Gene Expression Regulation, Neoplastic/*physiology
Multiple Myeloma/*genetics
Multiple Myeloma/*therapy
Transcriptome/*physiology
Humans ; In Situ Hybridization, Fluorescence ; Recurrence ; Risk ; Transplantation, Autologous

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis.
Autorzy:: Andersen JP; Medical Library, Aalborg University Hospital, Aalborg, Denmark.
Bøgsted M; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Dybkær K; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Mellqvist UH; Department of Hematology Sahlgrenska Hospital, Gothenburg, Sweden; European Myeloma Network Board, Aalborg, Denmark.
Morgan GJ; The Institute of Cancer Research Haematology & Oncology, London, United Kingdom; European Myeloma Network Board, Aalborg, Denmark.
Goldschmidt H; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; European Myeloma Network Board, Aalborg, Denmark.
Dimopoulos MA; Department of Clinical Therapeutics, University of Athens, Alexandra General Hospital, Athens, Greece; European Myeloma Network Board, Aalborg, Denmark.
Einsele H; Department of Internal Medicine II, University of Würzburg, Würzburg, Germany; European Myeloma Network Board, Aalborg, Denmark.
San Miguel J; Universidad de Navarra, Pamplona, Spain; European Myeloma Network Board, Aalborg, Denmark.
Palumbo A; Department of Hematology, University of Turin, Turin, Italy; European Myeloma Network Board, Aalborg, Denmark.
Sonneveld P; Erasmus University Hospital, Department of Hematology, Rotterdam, The Netherlands; European Myeloma Network Board, Aalborg, Denmark.
Johnsen HE; Department of Haematology, Aalborg University Hospital, Aalborg, Denmark; European Myeloma Network Board, Aalborg, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2015 Jan 28; Vol. 10 (1), pp. e0116966. Date of Electronic Publication: 2015 Jan 28 (Print Publication: 2015).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Bibliometrics*
Multiple Myeloma*
Publications*
Research*
Cluster Analysis ; Humans ; Reproducibility of Results ; Time Factors

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.
Autorzy:: Brioli A; Myeloma Research Centre, Division of Molecular Pathology, The Institute of Cancer Research , London , UK.
Melchor L
Titley I
Vijayaraghavan G
Stephens C
Zeisig A
Pawlyn C
Cavo M
Morilla R
Davies FE
Morgan GJ; Pokaż więcej
Źródło:: Leukemia & lymphoma [Leuk Lymphoma] 2014 Nov; Vol. 55 (11), pp. 2665-8. Date of Electronic Publication: 2014 Apr 22.
Typ publikacji:: Letter
MeSH Terms:: Bone Marrow/*drug effects
Multiple Myeloma/*drug therapy
Thalidomide/*analogs & derivatives
Adult ; Aged ; Aged, 80 and over ; Bone Marrow/pathology ; Flow Cytometry ; Hematopoiesis/drug effects ; Humans ; Immunologic Factors/adverse effects ; Immunologic Factors/therapeutic use ; Lenalidomide ; Middle Aged ; Multiple Myeloma/blood ; Survival Analysis ; Thalidomide/adverse effects ; Thalidomide/therapeutic use ; Time Factors ; Treatment Outcome ; Young Adult

Opinia redakcyjna

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.
Autorzy:: Walker BA; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.
Wardell CP; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.
Melchor L; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.
Brioli A; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.; Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
Johnson DC; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.
Kaiser MF; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.
Mirabella F; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.
Lopez-Corral L; Department of Hematology of the University Hospital of Salamanca; Centro de Investigacion del Cancer (CIC) de Salamanca; and Instituto Biosanitario de Salamanca (IBSAL); Salamanca, Spain.
Humphray S; Illumina Cambridge Ltd., Chesterford Research Park, Little Chesterford, Saffron Walden, UK.
Murray L; Illumina Cambridge Ltd., Chesterford Research Park, Little Chesterford, Saffron Walden, UK.
Ross M; Illumina Cambridge Ltd., Chesterford Research Park, Little Chesterford, Saffron Walden, UK.
Bentley D; Illumina Cambridge Ltd., Chesterford Research Park, Little Chesterford, Saffron Walden, UK.
Gutiérrez NC; Department of Hematology of the University Hospital of Salamanca; Centro de Investigacion del Cancer (CIC) de Salamanca; and Instituto Biosanitario de Salamanca (IBSAL); Salamanca, Spain.
Garcia-Sanz R; Department of Hematology of the University Hospital of Salamanca; Centro de Investigacion del Cancer (CIC) de Salamanca; and Instituto Biosanitario de Salamanca (IBSAL); Salamanca, Spain.
San Miguel J; Department of Hematology of the University Hospital of Salamanca; Centro de Investigacion del Cancer (CIC) de Salamanca; and Instituto Biosanitario de Salamanca (IBSAL); Salamanca, Spain.
Davies FE; Targeted Myeloma Treatment, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.
Gonzalez D; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.
Morgan GJ; Molecular Haematology, Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, UK.; Pokaż więcej
Źródło:: Leukemia [Leukemia] 2014 Feb; Vol. 28 (2), pp. 384-390. Date of Electronic Publication: 2013 Jul 02.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Cell Transformation, Neoplastic/*genetics
Multiple Myeloma/*genetics
Cell Transformation, Neoplastic/metabolism ; Disease Progression ; Humans ; Monoclonal Gammopathy of Undetermined Significance/genetics ; Monoclonal Gammopathy of Undetermined Significance/metabolism ; Multiple Myeloma/diagnosis ; Multiple Myeloma/metabolism ; Mutation ; Translocation, Genetic

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma.
Autorzy:: Bøgsted M; Department of Haematology, Aalborg Hospital Science and Innovation Center (AHSIC), Aalborg University Hospital, Aalborg, Denmark ; Department of Mathematical Sciences, Aalborg University, Aalborg, Denmark.
Bilgrau AE; Department of Haematology, Aalborg Hospital Science and Innovation Center (AHSIC), Aalborg University Hospital, Aalborg, Denmark ; Department of Mathematical Sciences, Aalborg University, Aalborg, Denmark.
Wardell CP; Haemato-Oncology Research Unit, Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.
Bertsch U; Department of Internal Medicine V and National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.
Schmitz A; Department of Haematology, Aalborg Hospital Science and Innovation Center (AHSIC), Aalborg University Hospital, Aalborg, Denmark.
Bødker JS; Department of Haematology, Aalborg Hospital Science and Innovation Center (AHSIC), Aalborg University Hospital, Aalborg, Denmark.
Kjeldsen MK; Department of Haematology, Aalborg Hospital Science and Innovation Center (AHSIC), Aalborg University Hospital, Aalborg, Denmark.
Goldschmidt H; Department of Internal Medicine V and National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.
Morgan GJ; Haemato-Oncology Research Unit, Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.
Dybkaer K; Department of Haematology, Aalborg Hospital Science and Innovation Center (AHSIC), Aalborg University Hospital, Aalborg, Denmark.
Johnsen HE; Department of Haematology, Aalborg Hospital Science and Innovation Center (AHSIC), Aalborg University Hospital, Aalborg, Denmark.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2013 Dec 20; Vol. 8 (12), pp. e83252. Date of Electronic Publication: 2013 Dec 20 (Print Publication: 2013).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents/*pharmacology
B-Lymphocytes/*drug effects
Cyclin D/*genetics
Melphalan/*pharmacology
Multiple Myeloma/*genetics
Neoplasm Proteins/*genetics
Adult ; Aged ; Aged, 80 and over ; B-Lymphocytes/metabolism ; B-Lymphocytes/pathology ; Cell Line, Tumor ; Cyclin D/metabolism ; Drug Resistance, Neoplasm/genetics ; Female ; Gene Expression ; Gene Expression Profiling ; High-Throughput Screening Assays ; Humans ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Neoplasm Proteins/metabolism ; Survival Analysis ; Translocation, Genetic

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Morgan, Gareth"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język

Rok publikacji